PLT Health Solutions' Ceratiq Targets Sensitive Skin Market with New Clinical Data
PLT Health Solutions reports new clinical data for its Ceratiq phytoceramide ingredient, expanding its applications beyond hydration to sensitive skin support. This positions Ceratiq for increased market penetration in the burgeoning dermal health category.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 15 May 2024
PLT Health Solutions has unveiled new randomised clinical research on its Ceratiq ingredient, indicating benefits extending beyond traditional hydration and wrinkle reduction. The company asserts these unpublished studies demonstrate Ceratiq's capacity to support the structural integrity of sensitive skin and mitigate its reactivity. This represents a strategic expansion of Ceratiq's commercial application.
Ceratiq, a gluten-free, phytoceramide-rich wheat lipid extract, is positioned by PLT Health Solutions as an ingredient that strengthens the skin barrier and supports the dermal matrix. These functions are critical for maintaining skin density, firmness, hydration, and overall aesthetic smoothness. The emphasis on 'sensitive skin' introduces a distinct market opportunity for brand owners seeking to differentiate products in a crowded ingestible beauty sector.
The announcement, while based on un-published research, provides a forward look at potential new marketing claims. Manufacturers should monitor the publication of this data closely, as validated clinical endpoints for sensitive skin can command premium pricing and consumer trust. The gluten-free attribute further enhances its appeal in a market increasingly attentive to allergen declarations and clean label formulations.
Securing market claims related to 'sensitive skin' and 'reduced reactivity' could open doors to new retail channels and consumer demographics, particularly those seeking targeted solutions beyond general skin health. This development signals a move towards more specialised ingestible beauty formulations, demanding greater scrutiny of ingredient efficacy and provenance.
What this means for United Kingdom
UK brand owners can strategically position new product development to capture segments of the sensitive skin market, estimated at £200 million annually, utilising Ceratiq's new claims. Regulatory teams must prepare to substantiate these specific claims under FSA guidelines, ensuring robust clinical data is available post-publication. Competitive positioning will hinge on swift market entry with differentiated offerings, potentially establishing category leadership in sensitive skin nutraceuticals by Q4 2024. Procurement teams should evaluate Ceratiq for new formulations, considering its gluten-free status to meet growing consumer demand and broaden product appeal within the UK market.
This expanded efficacy profile suggests that ingredient suppliers are increasingly investing in specific clinical substantiation to command higher value and facilitate product differentiation for their customers. Brand owners must assess their current product portfolios against these evolving ingredient capabilities to maintain competitive advantage.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.